Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Dea ChotzalliDepartment of Pharmacy, Division of Pharmaceutical Chemistry, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece.ORCID 0009-0004-6843-5630
Vasiliki PardaliDepartment of Pharmacy, Division of Pharmaceutical Chemistry, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece.
Holly M WaldenMolecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA.
Dimitrios PerivolarisDepartment of Pharmacy, Division of Pharmaceutical Chemistry, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece.
Dimitrios MoianosDepartment of Pharmacy, Division of Pharmaceutical Chemistry, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece.ORCID 0000-0001-8843-0950
Maria MakriDepartment of Pharmacy, Division of Pharmaceutical Chemistry, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece.
Antonios DrakopoulosDepartment of Chemistry and Molecular Biology, University of Gothenburg, 41296 Göteborg, Sweden.ORCID 0000-0001-9178-7213
Erofili GiannakopoulouDepartment of Pharmacy, Division of Pharmaceutical Chemistry, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece.ORCID 0000-0003-2564-6628
Razia TajwarMolecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA.
Molly E WoodsonMolecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA.
John E TavisMolecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA.ORCID 0000-0002-8711-4240
Grigoris ZoidisDepartment of Pharmacy, Division of Pharmaceutical Chemistry, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece.ORCID 0000-0002-9442-5186
Funding
Lead optimization of Hepatitis B Virus ribonuclease H inhibitorsR01AI150610 · NIAID · SAINT LOUIS UNIVERSITY · PI MEYERS, MARVIN J, TAVIS, JOHN E · 2021 to 2025
$3.3M
HBV RNaseH inhibitors: Effects on HBV biology and resistance developmentR01AI148362 · NIAID · SAINT LOUIS UNIVERSITY · PI TAVIS, JOHN E · 2020 to 2024
$1.9M
European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement 945380NIAID NIH HHS R01 AI148362NIAID NIH HHS R01 AI150610NIH HHS 1R01AI148362-20NIH HHS 1R01AI150610-21
6 · The paper itself
Abstract
Hepatitis B Virus (HBV) continues to pose a significant global health challenge, with over 254 million chronic infections and current therapies being non-curative, necessitating lifelong treatment. The HBV ribonuclease H (RNase H) is essential during HBV reverse transcription by cleaving the viral pregenomic RNA after it has been copied into the (-) polarity DNA strand, enabling the viral polymerase to synthesize the (+) DNA strand. Although RNase H inhibition terminates viral replication and thus viral infectiveness, its targeting as an HBV treatment is unexploited. Its catalytic site contains four carboxylates that bind to two Mg
Indexed as
Antiviral AgentsEnzyme InhibitorsHepatitis B virusRibonuclease HDrug DesignDrug DiscoveryHumansMolecular Docking SimulationStructure-Activity RelationshipVirus ReplicationAntiviral AgentsEnzyme InhibitorsRibonuclease Hanti-HBV agentsHepatitis B virusiminesN-HydroxypyridinedionesoximesRibonuclease Hstructure-activity relationships
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.